Skip to main content
. 2025 Dec 10;13(6):178. doi: 10.3390/pharmacy13060178
AE Adverse Event
ARR Absolute Risk Reduction
CI Confidence Interval
COPD Chronic Obstructive Pulmonary Disease
DEMO Demographic/administrative file
DRUG Drug information file
EBGM Empirical Bayesian Geometric Mean
FAERS FDA Adverse Event Reporting System
FEV1 Forced Expiratory Volume in 1 s
FF Fluticasone Furoate
IC Information Component
ICS Inhaled Corticosteroid
IQR Inter Quartile Range
LABA Long-Acting Beta2 Agonist
LAMA Long-Acting Muscarinic Antagonist
MedDRA Medical Dictionary for Regulatory Activities
PRR Proportional Reporting Ratio
PT Preferred Term
PS Primary Suspect
REAC Reaction file
ROR Reporting Odds Ratio
SOC System Organ Class
SGRQ St. George’s Respiratory Questionnaire
TTO Time-To-Onset
UMEC Umeclidinium
VI Vilanterol